BioSpace News Archive

Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced the pricing of an underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share.

LumaCyte is proud to announce the launch of their newly redesigned flagship Radiance® instrument to meet growing demand for Laser Force Cytology™ precision analytics in space-constrained biomanufacturing facilities.

Conformal Medical, Inc. announced the positive one-year results from the company’s CONFORMAL Early Feasibility Study.

A retrospective study undertaken by Maccabi KSM Research in Israel has revealed that the Pfizer COVID-19 vaccine offers the same level of protection against the virus for patients with Celiac Disease as it does for those without this chronic condition.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Glycologix, Inc. (“Glycologix”), a clinical-stage company focused on developing biopolymers for the protection and repair of soft tissues, today announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

Data from the REAL-PE study was presented at TCT, the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating that patients treated for pulmonary embolism with the Boston Scientific EKOS™ Endovascular System had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the Inari FlowTriever® System.

Servier today announced the U.S. Food and Drug Administration (FDA) has approved TIBSOVO® (ivosidenib tablets) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) announces the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP).

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.